Carl H. June | Academic Influence

Why Is Carl H. June Influential?

According to Wikipedia, Carl H. June is an American immunologist and oncologist. He is currently the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania. He is most well known for his research into T cell therapies for the treatment of cancer. In 2020 he was elected to the American Philosophical Society.

Carl H. June's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Papers

Chimeric antigen receptor T cells for sustained remissions in leukemia. (3464)
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. (2769)
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. (2600)
Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia (2167)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia (1979)
A human memory T-cell subset with stem cell-like properties (1305)
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. (1295)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia (1146)
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. (1145)
The B7 and CD28 receptor families. (1144)
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. (1135)
CAR T cell immunotherapy for human cancer (1124)
Cytokine release syndrome in severe COVID-19 (1105)
The CD28 signaling pathway regulates glucose metabolism. (1070)
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases (968)
SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 (948)
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. (937)
Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. (918)
Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas (902)
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. (881)
Chimeric Antigen Receptor Therapy. (840)
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. (800)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma (761)
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains (714)
Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1 (712)
Engineered T cells: the promise and challenges of cancer immunotherapy (708)
Delivery technologies for cancer immunotherapy (674)
Role of the CD28 receptor in T-cell activation. (654)
CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. (649)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia (638)
The Principles of Engineering Immune Cells to Treat Cancer (619)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. (612)
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies (592)
NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma (586)
T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. (536)
Antibody-modified T cells: CARs take the front seat for hematologic malignancies. (526)
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells (521)
Adoptive T cell therapy for cancer in the clinic. (514)
Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition (494)
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. (486)
Gene transfer in humans using a conditionally replicating lentiviral vector (485)
Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells (465)
Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction. (442)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. (439)
Isolation of a new herpesvirus from human CD4+ T cells. (429)
CRISPR-engineered T cells in patients with refractory cancer (425)
Human naive and memory T lymphocytes differ in telomeric length and replicative potential. (424)
Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB (419)
Regulated expression of telomerase activity in human T lymphocyte development and activation (414)
Human T regulatory cell therapy: take a billion or so and call me in the morning. (413)
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. (407)
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor (373)
L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. (365)
Increases in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation. (359)
Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. (354)
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. (353)
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells (352)
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. (346)
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. (340)
Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. (336)
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. (331)
Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma (325)
The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells (324)
Heterogeneity among T cells in intracellular free calcium responses after mitogen stimulation with PHA or anti-CD3. Simultaneous use of indo-1 and immunofluorescence with flow cytometry. (323)
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans (321)
Massive ex Vivo Expansion of Human Natural Regulatory T Cells (Tregs) with Minimal Loss of in Vivo Functional Activity (317)
Chimeric antigen receptor therapy for cancer. (304)
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. (303)
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. (301)
ASSOCIATION BETWEEN CYCLOSPORIN NEUROTOXICITY AND HYPOMAGNESAEMIA (300)
Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors (299)
Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. (298)
In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. (297)
The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. (297)
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. (296)
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer (295)
PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. (295)
Cytokine Storm (288)
Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cells (285)
An inducible cytoplasmic factor (AU-B) binds selectively to AUUUA multimers in the 3' untranslated region of lymphokine mRNA. (284)
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell (282)
Adoptive cellular therapy: A race to the finish line (280)
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. (279)
Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors (276)
Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. (271)
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia (267)
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. (266)
Is autoimmunity the Achilles' heel of cancer immunotherapy? (266)
Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies (266)
Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity (266)
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia (263)
Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. (259)
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. (255)
Principles of adoptive T cell cancer therapy. (255)
Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo (250)
CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. (248)
A versatile system for rapid multiplex genome-edited CAR T cell generation (247)
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. (246)
A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. (245)
Genetic therapies against HIV (243)
Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. (243)
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. (242)
Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. (242)
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor (238)
Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. (237)
Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. (237)
Human chimeric antigen receptor macrophages for cancer immunotherapy (237)
In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). (235)
cis-acting sequences required for inducible interleukin-2 enhancer function bind a novel Ets-related protein, Elf-1. (231)
Adoptive immunotherapy for cancer or viruses. (229)
The B7 and CD28 receptor families (228)
Antiviral Effect and Ex Vivo CD4+ T Cell Proliferation in HIV-Positive Patients as a Result of CD28 Costimulation (227)
The NFAT-1 DNA binding complex in activated T cells contains Fra-1 and JunB. (217)
Monoclonal TCR-redirected tumor cell killing (216)
Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. (216)
The Inducible Costimulator (ICOS) Is Critical for the Development of Human TH17 Cells (216)
Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. (215)
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. (210)
Radiation and immunotherapy: a synergistic combination. (209)
Generation and Large‐Scale Expansion of Human Inducible Regulatory T Cells That Suppress Graft‐Versus‐Host Disease (204)
Cd40 Ligand (Cd154) Triggers a Short-Term Cd4+ T Cell Activation Response That Results in Secretion of Immunomodulatory Cytokines and Apoptosis (203)
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer (202)
Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging (199)
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. (197)
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18 (196)
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy (194)
Driving gene-engineered T cell immunotherapy of cancer (193)
Ibrutinib treatment improves T cell number and function in CLL patients (191)
Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells (189)
Engineering lymphocyte subsets: tools, trials and tribulations (187)
4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy1 (185)
Crosslinking of surface antigens causes mobilization of intracellular ionized calcium in T lymphocytes. (185)
PI 3-kinase: a pivotal pathway in T-cell activation? (181)
Lipopolysaccharide-induced protein tyrosine phosphorylation in human macrophages is mediated by CD14. (178)
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. (176)
A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes. (176)
Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection (176)
Cutting Edge: Foxp3-Mediated Induction of Pim 2 Allows Human T Regulatory Cells to Preferentially Expand in Rapamycin1 (175)
CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes. (170)
Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. (169)
CD28 and Inducible Costimulatory Protein Src Homology 2 Binding Domains Show Distinct Regulation of Phosphatidylinositol 3-Kinase, Bcl-xL, and IL-2 Expression in Primary Human CD4 T Lymphocytes 1 (168)
Emerging Cellular Therapies for Cancer. (168)
Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. (165)
IgE secretion by Epstein-Barr virus-infected purified human B lymphocytes is stimulated by interleukin 4 and suppressed by interferon gamma. (165)
Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. (163)
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer (158)
Treatment of advanced leukemia in mice with mRNA engineered T cells. (158)
Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. (157)
Targeting Cardiac Fibrosis with Engineered T cells (156)
CD28 Costimulation Is Essential for Human T Regulatory Expansion and Function1 (156)
Growth factors can enhance lymphocyte survival without committing the cell to undergo cell division. (156)
Signal transduction through cd4 receptors: stimulatory vs. inhibitory activity is regulated by cd4 proximity to the cd31t cell receptor (153)
AU RNA-binding factors differ in their binding specificities and affinities. (151)
CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. (148)
A Phase I Clinical Trial of Single-Dose Intrapleural IFN-β Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses (146)
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. (146)
Engineering HIV-Resistant Human CD4+ T Cells with CXCR4-Specific Zinc-Finger Nucleases (141)
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. (140)
Monoclonal antibody-defined functional epitopes on the adhesion-promoting glycoprotein complex (CDw18) of human neutrophils. (140)
Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. (140)
CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. (139)
Defining the critical hurdles in cancer immunotherapy (137)
Cutting Edge: CTLA-4 Ligation Delivers a Unique Signal to Resting Human CD4 T Cells That Inhibits Interleukin-2 Secretion but Allows Bcl-XL Induction (136)
Distinct signal transduction in mouse CD4+ and CD8+ splenic T cells after CD28 receptor ligation. (135)
Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. (134)
Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer (133)
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer (133)
Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. (133)
ICOS Costimulation Requires IL-2 and Can Be Prevented by CTLA-4 Engagement1 (132)
4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. (132)
Telomere Length, Telomerase Activity, and Replicative Potential in HIV Infection: Analysis of CD4+ and CD8+T Cells from HIV-discordant Monozygotic Twins (131)
Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. (130)
Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street (130)
Reciprocal expression of human ETS1 and ETS2 genes during T-cell activation: regulatory role for the protooncogene ETS1. (130)
Enhanced responsiveness of human memory T cells to CD2 and CD3 receptor‐mediated activation (128)
Tat-functionalized near-infrared emissive polymersomes for dendritic cell labeling. (127)
Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. (127)
The B 7 and CD 28 receptor families (126)
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade (126)
T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. (126)
Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. (125)
Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. (125)
Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager (125)
Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation. (124)
CD28 activation promotes Th2 subset differentiation by human CD4+ cells (124)
Inhibition of T cell receptor expression and function in immature CD4+CD8+ cells by CD4. (123)
Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. (122)
Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. (122)
Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. (120)
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance (119)
Regulation of TCR signaling by CD45 lacking transmembrane and extracellular domains. (118)
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. (117)
CD28 ligation in T-cell activation: evidence for two signal transduction pathways. (116)
Evidence for the involvement of three distinct signals in the induction of IL-2 gene expression in human T lymphocytes. (115)
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma (114)
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. (114)
Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019) (113)
IL-5 induces a Pgp-1 (CD44) bright B cell subpopulation that is highly enriched in proliferative and Ig secretory activity and binds to hyaluronate. (112)
CARs on track in the clinic. (112)
An HIV-1-infected T cell clone defective in IL-2 production and Ca2+ mobilization after CD3 stimulation. (110)
Regulation of telomerase RNA template expression in human T lymphocyte development and activation. (110)
HIV-1-infected T cells show a selective signaling defect after perturbation of CD3/antigen receptor. (108)
Costimulation of T cell receptor/CD3-mediated activation of resting human CD4+ T cells by leukocyte function-associated antigen-1 ligand intercellular cell adhesion molecule-1 involves prolonged inositol phospholipid hydrolysis and sustained increase of intracellular Ca2+ levels. (107)
Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. (107)
Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission (106)
Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells (106)
Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. (105)
CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges (105)
Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma (105)
Evidence for Distinct Intracellular Signaling Pathways in CD34+ Progenitor to Dendritic Cell Differentiation from a Human Cell Line Model (104)
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. (103)
Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology (103)
Mesothelin, a novel immunotherapy target for triple negative breast cancer (103)
Engineered T cells for cancer therapy (102)
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies (102)
Clinical perspectives for regulatory T cells in transplantation tolerance. (102)
Ionizable Lipid Nanoparticle Mediated mRNA Delivery for Human CAR T Cell Engineering. (101)
Clinical application of expanded CD4+25+ cells. (101)
Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity. (100)
Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. (100)
Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells (99)
Critical Requirement for the Membrane-Proximal Cytosolic Tyrosine Residue for CD28-Mediated Costimulation In Vivo1 (99)
TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. (98)
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia (96)
Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. (96)
Regulatory CD 4 1 CD 25 1 T Cells in Tumors from Patients with Early-Stage Non-Small Cell Lung Cancer and Late-Stage Ovarian Cancer 1 (96)
Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells (96)
Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. (95)
A Phase I Trial of Repeated Intrapleural Adenoviral-mediated Interferon-β Gene Transfer for Mesothelioma and Metastatic Pleural Effusions. (95)
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. (94)
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. (94)
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. (94)
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy. (92)
Multiple mechanisms regulate c‐myc gene expression during normal T cell activation. (90)
CD5 antibodies increase intracellular ionized calcium concentration in T cells. (90)
A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. (90)
CD40 ligand/CD40 stimulation regulates the production of IFN-gamma from human peripheral blood mononuclear cells in an IL-12- and/or CD28-dependent manner. (89)
Rapid Immune Recovery and Graft-versus-Host Disease–like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells (88)
Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. (87)
Optimization of the PiggyBac Transposon System for the Sustained Genetic Modification of Human T Lymphocytes (87)
Distinct patterns of transmembrane calcium flux and intracellular calcium mobilization after differentiation antigen cluster 2 (E rosette receptor) or 3 (T3) stimulation of human lymphocytes. (86)
Efficient priming of protein antigen-specific human CD4(+) T cells by monocyte-derived dendritic cells. (85)
Chimeric Antigen Receptor Therapy for B-cell Malignancies (85)
Productive Infection of Neonatal CD8+ T Lymphocytes by HIV-1 (84)
CAR T-Cell Therapies in Glioblastoma: A First Look (84)
Chemokine receptor 5 knockout strategies (83)
Regulatory T Cells and Human Myeloid Dendritic Cells Promote Tolerance via Programmed Death Ligand-1 (83)
Activation of tyrosine phosphorylation in human T cells via the CD2 pathway. Regulation by the CD45 tyrosine phosphatase. (83)
CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction. (82)
A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma. (82)
CD28‐deficient mice generate an impaired Th2 response to Schistosoma mansoni infection (81)
Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging. (81)
Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. (80)
Protection against lethal toxic shock by targeted disruption of the CD28 gene (80)
Patient monitoring and follow‐up in lentiviral clinical trials (79)
No T-cell tyrosine protein kinase signalling or calcium mobilization after CD4 association with HIV-1 or HIV-1 gp120 (79)
Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration. (79)
T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. (79)
A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. (78)
PROFOUND HYPOMAGNESEMIA AND RENAL MAGNESIUM WASTING ASSOCIATED WITH THE USE OF CYCLOSPORINE FOR MARROW TRANSPLANTATION (78)
CD28 dependence of T cell differentiation to IL-4 production varies with the particular type 2 immune response. (78)
Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion. (77)
The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations (77)
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors (77)
Transforming Growth Factor-β Receptor Blockade Augments the Effectiveness of Adoptive T-Cell Therapy of Established Solid Cancers (76)
The genomic organization of the CD28 gene. Implications for the regulation of CD28 mRNA expression and heterogeneity. (76)
Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 costimulation. (75)
Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms (75)
Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients (74)
Phorbol esters induce differentiation of human CD34+ hemopoietic progenitors to dendritic cells: evidence for protein kinase C-mediated signaling. (74)
In vivo calcium elevations in thymocytes with T cell receptors that are specific for self ligands. (73)
Naı̈ve and Memory CD4 T Cells Differ in Their Susceptibilities to Human Immunodeficiency Virus Type 1 Infection following CD28 Costimulation: Implications for Transmission and Pathogenesis (72)
Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas (70)
The CD45 tyrosine phosphatase regulates phosphotyrosine homeostasis and its loss reveals a novel pattern of late T cell receptor-induced Ca2+ oscillations (69)
Induction of calcium flux and enhancement of cytolytic activity in natural killer cells by cross-linking of the sheep erythrocyte binding protein (CD2) and the Fc-receptor (CD16). (69)
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. (68)
B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study (68)
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity. 1995. 3: 87-98. (68)
HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. (67)
Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts (67)
Genetic engineering of T cells for adoptive immunotherapy (67)
Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL (67)
Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights. (67)
The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL). (66)
Ultrasonography and computed tomography in severe urinary tract infection. (66)
Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12. (66)
Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. (65)
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. (65)
Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas (65)
Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL) (64)
CD28 ligation in T-cell activation: evidence for two signal transduction pathways. (64)
Adoptive transfer of simian immunodeficiency virus (SIV) naïve autologous CD4(+) cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status. (64)
Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. (64)
Inflammatory cytokines IFN-gamma plus TNF-alpha induce regulated expression of CD80 (B7-1) but not CD86 (B7-2) on murine fibroblasts. (64)
Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma (63)
Modulation of Susceptibility to HIV-1 Infection by the Cytotoxic T Lymphocyte Antigen 4 Costimulatory Molecule (63)
Correlation of hypomagnesemia with the onset of cyclosporine-associated hypertension in marrow transplant patients. (62)
Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer. (62)
Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction. (62)
Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate (61)
Immunotherapy opportunities in ovarian cancer (61)
Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia (61)
IL-21 promotes the expansion of CD27+CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells (61)
Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis (60)
Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy. (60)
Costimulatory approaches to adoptive immunotherapy. (60)
Nature of Tumor Control by Permanently and Transiently Modified GD2 Chimeric Antigen Receptor T Cells in Xenograft Models of Neuroblastoma (59)
Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM) (59)
Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (58)
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials (58)
Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (58)
Immunopathological aspects of Plasmodium berghei infection in five strains of mice. II. Immunopathology of cerebral and other tissue lesions during the infection. (57)
Stimulation of T cells through the CD3/T-cell receptor complex: role of cytoplasmic calcium, protein kinase C translocation, and phosphorylation of pp60c-src in the activation pathway. (57)
T-cell therapy at the threshold (57)
Putting the brakes on BTLA in T cell-mediated cancer immunotherapy. (57)
Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes (56)
Addition of Deoxynucleosides Enhances Human Immunodeficiency Virus Type 1 Integration and 2LTR Formation in Resting CD4+ T Cells (56)
Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. (56)
Novel Role of Phosphatidylinositol 3-Kinase in CD28-mediated Costimulation* (55)
Single residue in CD28-costimulated CAR T cells limits long-term persistence and antitumor durability. (55)
Driving cars to the clinic for solid tumors (55)
Human CD8+ T cells do not require the polarization of lipid rafts for activation and proliferation (55)
Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. (54)
Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells (54)
Immunotherapy for Brain Tumors. (54)
T-cell activation is required for efficient replication of human herpesvirus 6 (54)
Novel cell and gene therapies for HIV. (54)
Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. (53)
Stimulation of CD5 enhances signal transduction by the T cell antigen receptor. (53)
Opposing effects of CTLA4-Ig and Anti-CD80 (B7-1) plus Anti-CD86 (B7-2) on experimental allergic encephalomyelitis (52)
Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You (52)
Costimulation Light: Activation of CD4+ T Cells with CD80 or CD86 Rather Than Anti-CD28 Leads to a Th2 Cytokine Profile1 (51)
The protein tyrosine kinase inhibitor herbimycin A, but not genistein, specifically inhibits signal transduction by the T cell antigen receptor. (51)
Regulation of interleukin 3 gene induction in normal human T cells. (51)
Mitogen-induced genes are subject to multiple pathways of regulation in the initial stages of T-cell activation. (51)
T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. (50)
Prolonged survival and tissue trafficking following adoptive transfer of CD 4 z gene-modified autologous CD 4 1 and CD 8 1 T cells in human immunodeficiency virus – infected subjects (49)
Bi-specific and Split CAR T Cells Targeting CD13 and TIM3 Eradicate Acute Myeloid Leukemia. (49)
Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4. (48)
Engineering T cells for cancer: our synthetic future (48)
Mitogenic stimulation of T cells reveals differing contributions for B7‐1 (CD80) and B7‐2 (CD86) costimulation (48)
Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells (48)
Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer (48)
Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? (47)
Glycan-directed CAR-T cells (47)
Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig. (47)
Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules. (46)
Adoptive immunotherapy: good habits instilled at youth have long-term benefits (46)
T-cell immunotherapy: looking forward. (45)
CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. (45)
Primary porcine endothelial cells express membrane-bound B7-2 (CD86) and a soluble factor that co-stimulate cyclosporin A-resistant and CD28-dependent human T cell proliferation. (44)
Distinct Effects of IL-18 on the Engraftment and Function of Human Effector CD8+ T Cells and Regulatory T Cells (44)
CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells (44)
Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells. (44)
T-cell reconstitution and expansion after hematopoietic stem cell transplantation: ‘T’ it up! (44)
miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. (43)
Changing the Mindset in Life Sciences Toward Translation: A Consensus (42)
Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). (42)
Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. (42)
Potential roles of the B7 and CD28 receptor families in autoimmunity and immune evasion. (42)
Circulating and tissue-bound immune complex formation in murine malaria. (41)
Extensive Replicative Capacity of Human Central Memory T Cells1 (41)
Immunotherapy for Glioblastoma: Adoptive T-cell Strategies (41)
The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28–Costimulated T Cells Prepared for Adoptive Therapy (41)
Antigen-independent regulation of cytoplasmic calcium in B cells with a 12-kDa B-cell growth factor and anti-CD19. (41)
Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. (40)
Measurement of Intracellular Calcium Ions by Flow Cytometry (40)
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. (40)
NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus (39)
Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells (39)
Perspective: Assembly line immunotherapy (39)
Complex effects of phenylarsine oxide in T cells. Induction of tyrosine phosphorylation and calcium mobilization independent of CD45 expression. (39)
Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells (39)
The road to recovery: translating PD-1 biology into clinical benefit. (38)
Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence (38)
Signal transduction in T cells. (38)
Primary human CD4+ T cells contain heterogeneous I kappa B kinase complexes: role in activation of the IL-2 promoter. (38)
Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18 (37)
Rapid activation of C-Raf-1 after stimulation of the T-cell receptor or the muscarinic receptor type 1 in resting T cells. (37)
4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling (37)
Nanomaterials for T-cell cancer immunotherapy (37)
The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion. (37)
Persistent calcium elevation correlates with the induction of surface immunoglobulin-mediated B cell DNA synthesis (36)
Regulation of 4F2 heavy-chain gene expression during normal human T-cell activation can be mediated by multiple distinct molecular mechanisms. (36)
Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond. (36)
Role of CD2 cross‐linking in cytoplasmic calcium responses and T cell activation (36)
Dual CD 19 and CD 123 targeting prevents antigen-loss relapses after CD 19-directed immunotherapies (36)
Tumor Expression of 4-1BB Ligand Sustains Tumor Lytic T Cells (35)
Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. (35)
Adoptive Transfer of Autologous T Cells Improves T-cell Repertoire Diversity and Long-term B-cell Function in Pediatric Patients with Neuroblastoma (35)
Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL (35)
Enhanced transmembrane signalling activity of monoclonal antibody heteroconjugates suggests molecular interactions between receptors on the T cell surface. (34)
Flow cytometric measurement of intracellular ionized calcium in single cells with indo-1 and fluo-3. (34)
Surface immunoglobulin-mediated B-cell activation in the absence of detectable elevations in intracellular ionized calcium: a model for T-cell-independent B-cell activation. (34)
Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. (34)
Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. (34)
A translational bridge to cancer immunotherapy (34)
Tyrosine kinase-regulated and inositol phosphate-independent Ca2+ elevation and mobilization in T cells. (34)
Anti-CD3/anti-CD28 bead stimulation overcomes CD3 unresponsiveness in patients with head and neck squamous cell carcinoma. (33)
Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome. (33)
Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. (33)
A Novel System for Simultaneous in Vivo Tracking and Biological Assessment of Leukemia Cells and ex Vivo Generated Leukemia-Reactive Cytotoxic T Cells (33)
Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus (32)
Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL (32)
Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD (32)
Disseminated Fusarium moniliforme infection after allogeneic marrow transplantation. (32)
Considerations for the clinical application of chimeric antigen receptor T cells: Observations from a Recombinant DNA Advisory Committee symposium held June 15, 2010 (Cancer Research (2011) 71, (3175-3181)) (32)
CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL. (31)
Mesothelin expression is associated with poor outcomes in breast cancer (31)
The CD 28 Family : a T Cell Rheostat for Therapeutic Control of T Cell Activation (31)
Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. (31)
Cancer immunotherapy comes of age and looks for maturity (30)
Very-Low-Dose Streptozotocin Induces Diabetes in Insulin Promoter-mB7-1 Transgenic Mice (30)
Biochemical analysis of the immune B cell defect in xid mice. (30)
Measurement of CD69 induction in the assessment of immune function in asymptomatic HIV-infected individuals. (30)
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma (30)
Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice (30)
Two distinct mechanisms of interleukin-2 gene expression in human T lymphocytes. (30)
T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL (30)
Chapter 10 Intracellular Ionized Calcium (30)
Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation. (30)
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy (30)
Glucocorticoids suppress calcium mobilization and phospholipid hydrolysis in anti-Ig antibody-stimulated B cells. (29)
T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma (29)
Zoom Zoom: Racing CARs for Multiple Myeloma (29)
CD28 and staphylococcal enterotoxins synergize to induce MHC-independent T-cell proliferation. (29)
Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells. (29)
Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma. (28)
The CD28 and CTLA-4 receptor family. (28)
Transcription of T cell antigen receptor genes is induced by protein kinase C activation. (28)
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. (28)
B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis (27)
Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL. (27)
Immunotherapy for Breast Cancer: Current and Future Strategies (27)
Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model (27)
UV irradiation of lymphocytes triggers an increase in intracellular Ca2+ and prevents lectin-stimulated Ca2+ mobilization: evidence for UV- and nifedipine-sensitive Ca2+ channels. (27)
Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells. (27)
Interferon β adenoviral gene therapy in a patient with ovarian cancer (25)
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. (25)
A Cure for HIV Infection: “Not in My Lifetime” or “Just Around the Corner”? (25)
Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL (24)
Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL (24)
Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL. (24)
Ligand-stimulated signaling events in immature CD4+CD8+ thymocytes expressing competent T-cell receptor complexes. (24)
SAP: natural inhibitor or grand SLAM of T cell activation? (24)
Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide (24)
Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. (23)
Measurement of Intracellular Ions by Flow Cytometry (23)
Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety. (23)
Phosphatidylinositol 3-Kinase p110δ Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections (23)
T cell engineering as therapy for cancer and HIV: our synthetic future (23)
Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas. (23)
Lack of Coreceptor Allows Survival of Chronically Stimulated Double-Negative α/β T Cells (23)
Bimodal effect of phorbol ester on B cell activation. Implication for the role of protein kinase C. (23)
4-1BB costimulation promotes human T cell adhesion to fibronectin. (23)
Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. (22)
Anti-CD3/anti-CD28 monoclonal antibody-coated suture enhances the immune response of patients with head and neck squamous cell carcinoma. (22)
Anti-Ig-mediated proliferation of human B cells in the absence of protein kinase C. (22)
T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL (22)
Suppressor Function of Umbilical Cord Blood-Derived CD4+CD25+ T-Regulatory Cells Exposed to Graft-versus-Host Disease Drugs (22)
Intracellular ionized calcium. (22)
Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer. (21)
Immunopathological aspects of Plasmodium berghei infection in five strains of mice. I. Immune complexes and other serological features during the infection. (21)
Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers (21)
Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas (21)
Intracellular Survival Pathways against Glutamate Receptor Agonist Excitotoxicity in Cultured Neurons: Intracellular Calcium Responsesa (21)
Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment. (21)
A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. (21)
Long-Term Functional Persistence, B Cell Aplasia and Anti-Leukemia Efficacy In Refractory B Cell Malignancies Following T Cell Immunotherapy Using CAR-Redirected T Cells Targeting CD19 (21)
In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines (21)
The role of co-stimulation in regulation of chemokine receptor expression and HIV-1 infection in primary T lymphocytes. (20)
Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19 (20)
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. (20)
iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity (20)
Examination of the inhibitory and stimulatory effects of IFN-α, -β, and -γ on human B-cell proliferation induced by various B-cell mitogens (19)
Tumor-associated macrophages as a source of functional dendritic cells in ovarian cancer patients. (19)
Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (19)
Disease-Modifying Therapeutic Concepts for HIV in the Era of Highly Active Antiretroviral Therapy (18)
Flow cytometric measurement of cellular ionized calcium concentration. (18)
Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy (18)
Phase I/II Study of Pembrolizumab for Progressive Diffuse Large B Cell Lymphoma after Anti-CD19 Directed Chimeric Antigen Receptor Modified T Cell Therapy (18)
4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes. (18)
CD28 co-receptor signal transduction in T-cell activation. (18)
Activation of human B lymphocytes by nanogram concentrations of anti‐IgM‐dextran conjugates (17)
Drugging the Undruggable Ras - Immunotherapy to the Rescue? (17)
Chimeric Antigen Receptor T Cells in Myeloma. (17)
Different patterns of inositol polyphosphate production are seen in B lymphocytes after cross-linking of sIg by anti-Ig antibody or by a multivalent anti-Ig antibody dextran conjugate. (17)
Ruxolitinib Prevents Cytokine Release Syndrome after Car T-Cell Therapy Without Impairing the Anti-Tumor Effect in a Xenograft Model (17)
Phase I clinical trial of donor T-helper type-2 cells after immunoablative, reduced intensity allogeneic PBSC transplant. (17)
CARTs on the Road for Myeloma (16)
Defective signal transduction by the CD2 molecule in immature T-cell receptor/CD3- thymocytes. (16)
Variations in thymocyte susceptibility to clonal deletion during ontogeny. Implications for neonatal tolerance. (16)
T-Cell Immunotherapy: Looking Forward: T Cell Immunotherapy: Optimizing Trial Design Bethesda, Maryland 10-11 September 2013. (16)
A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor positive cells. (16)
Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia (16)
Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation. (16)
Adoptive cellular therapy. (16)
CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc). (15)
Phase I Trial of Adoptive Cell Transfer with Mixed-Profile Type-I/Type-II Allogeneic T Cells for Metastatic Breast Cancer (15)
Cross-linkage of Ly-6A/E induces Ca2+ translocation in the absence of phosphatidylinositol turnover and mediates proliferation of normal murine B lymphocytes. (15)
Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia (15)
Development of an animal model for autotransfusion therapy: in vitro characterization and analysis of anti-CD3/CD28 expanded cells. (15)
The CD28 and CTLA-4 Receptor Family (Part 1 of 2) (15)
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. (15)
Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma (15)
Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma. (14)
T-cell-targeted immunotherapy. (14)
A rational mouse model to detect on-target off-tumor CAR T cell toxicity. (14)
Detection of antigen specific T lymphocytes by determination of intracellular calcium concentration using flow cytometry. (14)
Adoptive Transfer of Gene-Modified T-Cells Engineered to Express High-Affinity TCRs for Cancer-Testis Antigens (CTAs) NY-ESO-1 or Lage-1, in MM Patients Post Auto-SCT (14)
PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells (14)
Analysis of antigen receptor signaling in B cells from mice with a retrovirus-induced acquired immunodeficiency syndrome. (14)
FoxP3 Mediated Induction of Pim 2 Allows T Regulatory Cells to Preferentially Expand in Rapamycin (14)
Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms (13)
Abstract 4575: Chimeric antigen receptor macrophages (CARMA) for adoptive cellular immunotherapy of solid tumors (13)
Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans. (13)
Multiplex Cripsr/Cas9 Genome Editing to Generate Potent Universal CART and PD1-Deficient Cells Against Leukemia (13)
Trispecific antibodies offer a third way forward for anticancer immunotherapy (13)
Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR (13)
Calcium-independent calcineurin regulation (13)
CARs on Track in the Clinic: Workshop of the Blood and Marrow Transplant Clinical Trials Network Subcommittee on Cell and Gene Therapy Washington DC, 18 May 2010. (13)
Protein kinase C activation in B cells by indolactam inhibits anti-Ig-mediated phosphatidylinositol bisphosphate hydrolysis but not B cell proliferation. (12)
Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma (12)
Measurement of Intracellular Ions by Flow Cytometry (12)
Adoptive Therapy with T Cells/NK Cells (12)
Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. (12)
TRANCE-and CD 40 Ligand-matured Dendritic Cells Reveal MHC Class I-restricted T Cells Specific for Autologous Tumor in Late-Stage Ovarian Cancer Patients 1 (12)
Absorbable microparticulate cation exchanger for immunotherapeutic delivery. (12)
Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors (12)
The promise of T-lymphocyte immunotherapy for the treatment of malignant disease. (12)
Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL). (12)
Efficient Termination of CD123-Redirected Chimeric Antigen Receptor T Cells for Acute Myeloid Leukemia to Mitigate Toxicity (12)
Adoptive Transfer of Umbilical Cord Blood (UCB)-Derived Regulatory T Cells (Tregs) to Recipients of Nonmyeloablative Unrelated Double UCB Transplantation. (11)
Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014. (11)
Lack of coreceptor allows survival of chronically stimulated double-negative alpha/beta T cells: implications for autoimmunity. (11)
Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation (11)
Anti-CD123 Chimeric Antigen Receptor T Cells (CART-123) Provide A Novel Myeloablative Conditioning Regimen That Eradicates Human Acute Myeloid Leukemia In Preclinical Models (11)
Predicting cytokine storms: it's about density. (11)
Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic‐Pharmacodynamic Modeling Approaches (11)
Novel Chimeric Antigen Receptor T Cells for the Treatment of Hodgkin Lymphoma (11)
CCR5-edited CD4 T cells augment HIV-specific immunity to enable post rebound control of HIV replication. (11)
Anti-CD 19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma (11)
CD19‐DIRECTED CAR T CELL THERAPY (CTL019) FOR RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL AND FOLLICULAR LYMPHOMAS: FOUR YEAR OUTCOMES (10)
Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies (10)
Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells (10)
Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy. (10)
Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. (10)
Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma (10)
Blocking HIV's attack. (10)
Measurements of Cell Physiology: Ionized Calcium, pH and Glutathione (10)
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. (10)
IMCT-15PILOT STUDY OF T CELLS REDIRECTED TO EGFRvIII WITH A CHIMERIC ANTIGEN RECEPTOR IN PATIENTS WITH EGFRvIII+ GLIOBLASTOMA (10)
CAR T cell viability release testing and clinical outcomes: is there a lower limit? (10)
Impaired Induction of the Apoptosis-Protective Protein Bcl-xL in Activated PBMC from Asymptomatic HIV-Infected Individuals (10)
Emerging Use of CRISPR Technology - Chasing the Elusive HIV Cure. (10)
Adoptive immunotherapy: new ways to skin the cat? (10)
Improved detection of immune complexes in human and mouse serum using a microassay adaptation of the C1Q binding test. (10)
Introduction to Functional Cell Assays (10)
Differential sensitivity of human leukocyte subpopulations to ultraviolet light. (10)
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD 3 / CD 28 costimulation (10)
203. Shortened T Cell Culture with IL-7 and IL-15 Provides the Most Potent Chimeric Antigen Receptor (CAR)-Modified T Cells for Adoptive Immunotherapy (9)
Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019). (9)
First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. (9)
Monoclonal TCR-redirected tumor cell killing. Nat Med (9)
Post-transplant adoptive T-cell immunotherapy. (9)
Correction: CD28-deficient mice generate and impaired th2 response to Schistosoma mansoni infection (European Journal of Immunology (1996) 26 (10) (2448-2455)) (9)
Targeting CLEC12A with Chimeric Antigen Receptor T Cells Can Overcome the Chemotherapy Refractoriness of Leukemia Stem Cells (9)
Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design (9)
Interferon beta adenoviral gene therapy in a patient with ovarian cancer. (9)
Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia (8)
Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM) (8)
Humanized chimeric antigen receptor (CAR)-modified T cells targeting CD19 induce remissions in children and young adults with relapsed/refractory lymphoblastic leukemia/lymphoma (8)
Cellular and growth-factor requirements for the replication of human herpesvirus 6 in primary lymphocyte cultures. (8)
Toward synthetic biology with engineered T cells: a long journey just begun. (8)
CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL). (8)
Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia. (7)
Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study (7)
Intact antigen receptor-mediated calcium signals in patients with early stage HIV-1 infection. (7)
The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function (7)
CD 28 IS AN INDUCIBLE T CELL SURFACE ANTIGEN THAT TRANSDUCES A : PROLIFERATIVE SIGNAL IN CD 3 MATURE THYMOCYTES ' (7)
Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies (7)
CTL019 Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor (CAR) T Cells to Characterize the Impact of Tocilizumab on Expansion and to Identify Correlates of Cytokine Release Syndrome Severity (7)
Signal transduction by B and T cells early after bone marrow transplantation: B cell calcium flux responses are intact whereas lack of CD4 cells accounts for impaired T cell responses. (7)
Ex vivo replicative potential of adult human peripheral blood CD4+ T cells. (7)
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells (7)
Distinct Signaling By Chimeric Antigen Receptors (CARs) Containing CD28 Signaling Domain Versus 4-1BB In Primary Human T Cells (7)
Programming the next generation of dendritic cells. (7)
Boosting engineered T cells (7)
High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses (7)
Remote Controlled CARs: Towards a Safer Therapy for Leukemia (7)
The cytological features of CAR(T) cells (7)
CAR T cells produced in vivo to treat cardiac injury (7)
Multiple cancer-specific antigens are targeted by a chimeric antibody receptor on a single cancer cell. (7)
Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells (6)
Engineered T Cell Therapies from a Drug Development Viewpoint (6)
Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy (6)
Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL) (6)
Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications (6)
Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL (6)
CD4 T cells to kiss off chemotherapy-resistant CMV? (6)
Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of epigenome. (6)
B lymphocyte immunoglobulin receptor desensitization is downstream of tyrosine kinase activation. (6)
Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. (6)
CTL019 Clinical Pharmacology and Biopharmaceutics in Pediatric Patients with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) (6)
Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts (6)
Examination of the inhibitory and stimulatory effects of IFN-alpha, -beta, and -gamma on human B-cell proliferation induced by various B-cell mitogens. (6)
Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism (6)
Measurement of Intracellular Ions by Flow Cytometry (5)
T-Rapa Cell Clinical Products Contain a Balance of Minimally Differentiated Th2/Th1 Effector Cells Depleted of Treg Cells (5)
Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation (5)
Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells (5)
Phase I trial of autologous cMET-directed CAR-t cells administered intravenously in patients with melanoma & breast carcinoma. (5)
Use of cell-based therapies for modification of host immune responses. (5)
Ultrasonography and Computed Tomography in Severe Urinary Tract Infection (5)
A phase II, dose-optimization trial of autologous T cells genetically engineered to express anti-CD19 chimeric antigen receptor (CART-19) in patients with relapsed or refractory (r/r) CD19+ chronic lymphocytic leukemia (CLL). (5)
Combination Immunotherapy After ASCT for Multiple Myeloma (MM) Using MAGE-A3/Poly-ICLC Immunizations Followed by Vaccine-Primed and Activated Autologous T-Cells (5)
974. Towards Gene Knock out Therapy for AIDS/HIV: Targeted Disruption of CCR5 Using Engineered Zinc Finger Protein Nucleases (ZFNs) (5)
Signal transduction properties of the T cell activation monoclonal antibody panel: ubiquitous increase in cellular substrate tyrosine phosphorylation in the absence of detectable calcium mobilization. (5)
Stimulation of T cells through the CD3/T-cell receptor complex: role of cytoplasmic calcium, protein kinase C translocation, and phosphorylation of pp60c-src in the activation pathway (5)
TCancer Patients Directly Inhibit Autologous Cutting Edge : Regulatory T Cells from Lung (5)
758. Towards Gene Knock out Therapy for AIDS/HIV: Targeted Disruption of CCR5 Using Engineered Zinc Finger Protein Nucleases (ZFNs) (5)
Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy (5)
An NK-like CAR T cell transition in CAR T cell dysfunction (5)
Title: Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells Short Title: Constitutive CAR T-cell proliferation (5)
Alcoholic ketoacidosis and isopropyl alcohol intoxication. (5)
Analysis of lymphocyte activation and metabolism by flow cytometry. (4)
Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma (4)
Microenvironment and Immunology Enhanced Effector Responses in Activated CD 8 þ T Cells De fi cient in Diacylglycerol Kinases (4)
A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. (4)
CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia (4)
Responsiveness of fetal and adult CD4-, CD8- thymocytes to T cell activation. (4)
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. (4)
Abstract PR06: T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce complete responses and long-term persistence without GVHD in children with relapsed, refractory ALL (4)
Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment (4)
Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models (4)
638. TGFBeta Signaling Blockade within PSMA Targeted CAR Human T Cells for the Eradication of Metastatic Prostate Cancer (4)
BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. (4)
Biomarker Profiling Differentiates Sepsis from Cytokine Release Syndrome in Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) (4)
Long-Term Remission of CLL Sustained By Pauciclonal Anti-CD19 Chimeric Antigen Receptor T (CTL019) Cell Clones (3)
Stimulation of CD 5 Enhances Signal Transduction by the T Cell Antigen Receptor (3)
Distinct Roles for B 7-1 ( CD-80 ) and B 7-2 ( CD-86 ) in the Initiation of Experimental Allergic Encephalomyelitis (3)
Isolation of a new herpes-virus from human CD4+ T cells (3)
Expression of the human epidermal growth factor receptor in a murine T-cell hybridoma. A transmembrane protein tyrosine kinase can synergize with the T-cell antigen receptor. (3)
Adoptive immunotherapy with autologous CD3/CD28-costimulated T cells after fludarabine-based chemotherapy in patients with chronic lymphocytic leukemia. (3)
A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. (3)
Enhancing Graft-vs-Tumor (GVT) Activity of Donor Leukocyte Infusions by Ex-Vivo Expansion and Activation with CD3/CD28 Co-Stimulation. (3)
Signal Transduction in T Cell Activation and Tolerance (3)
Abstract 3525: IMCgp100: A novel bi-specific biologic for the treatment of malignant melanoma (3)
Production of Human CRISPR-Engineered CAR-T Cells. (3)
Monosomy 1p36 uncovers a role for OX40 in survival of activated CD4+ T cells. (3)
Effect of chimeric antigen receptor (CAR) T cells on clonal expansion of endogenous non-CAR T cells in patients (pts) with advanced solid cancer. (3)
Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia (3)
Adoptive Transfer of Treg-Depleted Donor Th1 and Th2 Cells Safely Accelerates Alloengraftment After Low-Intensity Chemotherapy (3)
Adoptive transfer of ex vivo costimulated autologous T-cells after autotransplantation for myeloma (MM)accelerates post-transplant T-cell recovery (3)
Serial Killers and Mass Murderers: Engineered T Cells Are up to the Task (3)
T Cell Immunotherapy: Optimizing Trial Design (3)
Potential Clinical Applications of Signal Transduction Measurements in Marrow Transplantation and HIV‐1 Infection a (3)
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia (3)
Cancer Killers. (3)
Adoptive Transfer of Ex Vivo Costimulated Autologous T-Cells in Conjunction with Pneumococcal Conjugate Vaccine Immunizations Accelerates Post-Transplant T-Cell Recovery after Autotransplantation for Myeloma: Results of a Randomized Study. (3)
CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells (3)
Impact of Humoral Immunogenicity (Anti-mCAR19 Antibodies) on CTL019 Cellular Kinetics, Efficacy, and Safety (3)
180 - Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in Non-Hodgkin Lymphoma (NHL) (3)
The 4F2 heavy chain gene: a molecular model of inducible gene expression in human T cells. (3)
Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia (3)
CD33 Directed Chimeric Antigen Receptor T Cell Therapy As a Novel Preparative Regimen Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia (3)
Adoptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells (ACTC) Enhances Numeric and Functional Lymphocyte Recovery after Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma. (3)
1003. HIV-1-Derived Lentivirus Vector-Based Antisense Gene Therapy: Towards an Alternative Treatment for HIV/AIDS (2)
211. CD2, the First Identified T cell Co-Stimulator, Demonstrates More Effective Chimeric Antigen Receptor Activity Over CD28 and 4-1BB (2)
CAR T Cells Secreting IL18 Augment Antitumor Immunity and Increase T Cell Proliferation and Costimulation (2)
515. Oncolytic Adenovirus Armed with Cytokines Enhances CAR-T Cell Efficacy in Pancreatic Tumor Model (2)
tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells (2)
Improved Anti-Leukemia Activities of Adoptively Transferred T Cells Expressing Bites (2)
Pre-clinical validation of a humanized anti-EGFR variant III chimeric antigen receptor and phase I trial of CART-EGFRvIII in glioblastoma (2)
Abstract LB-156: Improved T cell survival, tumor localization and tumor eradication by folate receptor-alpha redirected T cells is achieved by provision of CD137 costimulatory signaling (2)
Oncolytic Adenovirus Expressing Cytokines Enhances Anti-Tumor Efficacy of Mesothelin-Redirected CAR-T Cells (2)
Adaptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells Enhances Lymphocyte Recovery after Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma. (2)
First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies (2)
76 – Principles of tumor immunology (2)
T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression (2)
Bioluminescent Tracking of Human and Mouse Acute Lymphoblastic Leukemia Reveals Potent Immunogenicity of Luciferase In Some Preclinical Models of Leukemia (2)
Pilot study of redirected autologous T cells engineered to contain anti-CD19 attached to TCRζ and 4-1BB signaling domains in patients with chemotherapy-resistant or -refractory CD19+ leukemia and lymphoma. (2)
Response from Carroll et al. (2)
This information is current as Autoimmune Encephalomyelitis Onset Ameliorates Experimental of Encephalitogenic T Cells or After Disease Blockade of CD 28 During In Vitro Activation (2)
Miniatures Mesothelin-Speci fi c Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies (2)
Adoptive transfer of gene-modified T-cells engineered to express high-affinity tcr's for cancer-testis antigens NY-ESO-1 or lage-1, in multiple myeloma (MM) patients post autologous hematopoietic stem cell transplant (ASCT) (2)
Can't Get Any Help? New Approaches for Adoptive Immunotherapy of Cancer. (2)
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. (2)
Utility of FDG-PET/CT in lymphoma patients undergoing immunotherapy with autologous CTL019 T-cells. (2)
Sustained Functional T Cell Persistence and B Cell Aplasia Following CD19-Targeting Adoptive T Cell Immunotherapy for Relapsed, Refractory CD19+ Malignacy (2)
Enhancing T cell persistence of CAR-redirected T cells in solid tumors (2)
L-selectin expression defines a subpopulation of In vitro generated AML-reactive T-cells with superior anti-leukemic efficacy for adoptive immunotherapy (2)
Abstract 3749: Genetic blockade of the protein tyrosine phosphatase SHP1 augments CAR T cell activity against PDL1 expressing solid tumors (2)
Impaired tumor death receptor signaling drives resistance to CAR T cell therapy (2)
Abstract LB-083: Phase I study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma (2)
Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control (2)
Author Correction: Targeting cardiac fibrosis with engineered T cells (2)
69. Adoptive T-cell Therapy for Malignancy in the Setting of Hematopoietic Cell Transplantation (2)
30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015). (2)
T-Rapa Cell DLI Safely Balances Th1/Th2 Cytokine Activation After Low-Intensity Allogeneic Hematopoietic Cell Transplantation (2)
Productive Infection of Neonatal CD 8 1 T Lymphocytes by HIV-1 By (2)
Comparative trial of imipenem and moxalactam in the treatment of serious bacterial infections (2)
Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation (2)
On the nature of early mortality in murine malaria. (2)
Studying Immunoreceptor Signaling in Human T Cells Using Electroporation of In Vitro Transcribed mRNA. (1)
Methods for selectively stimulating the proliferation of T-cells (1)
T Regulatory Expansion and Function CD 28 Costimulation Is Essential for Human June and (1)
Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma (1)
Are affinity-enhanced T cells the future of HIV therapy? (1)
CAR T cells targeting CD13 controllably induce eradication of acute myeloid leukemia with a single domain antibody switch (1)
Decade-long remissions of leukemia sustained by the persistence of activated CD4+ CAR T-cells (1)
515. Targeting Hypoglycosylation with a Chimeric Antigen Receptor (1)
Prophylactic Administration Of Ex VIVO Co-Stimulated Donor Lymphocyte Infusion (DLI) From Related And Unrelated Donors After Reduced Intensity Conditioning For High Risk Hematologic Malignancies (1)
Engineered T-Cells Expressing An HLA-Restricted Affinity-Enhanced TCR In Advanced Multiple Myeloma Patients Post Auto-SCT Engraft and Are Associated With Encouraging Post Auto-SCT Responses (1)
Circulating immune complexes in malaria. (1)
The CD28 and CTLA-4 Receptor Family (Part 2 of 2) (1)
Abstract A123: Skewed CD4 and CD8 T-cell differentiation in pancreatic cancer patients (1)
Towards Phase 2/3 Trials for Epstein - Barr Virus (EBV)-Associated Malignancies, (1)
Rethinking the Regulatory Infrastructure for Human Gene Transfer Clinical Trials. (1)
transposon system Sleeping Beauty Stable gene transfer and expression in human primary T cells by the (1)
Gene expression signatures of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with CLL and ALL. (1)
Co-stimulated autologous T-cell infusion after autologous stem cell transplantation (SCT) for myeloma accelerates lymphocyte recovery and augments response to pneumoccal vaccine: Results of a randomized trial (1)
AACR Calls on Congress to Take Immediate Action Against COVID-19 and Protect Patients with Cancer During the Pandemic. (1)
Series ANTIBODY DERIVATIVES AS NEW THERAPEUTICS FOR HEMATOLOGIC MALIGNANCIES Antibody-modi fi ed T cells : CARs take the front seat for hematologic malignancies (1)
Additional file 4: of iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity (1)
Single-cell antigen-specific activation landscape of CAR T infusion product identifies determinants of CD19 positive relapse in patients with ALL (1)
malignancies Antibody-modified T cells: CARs take the front seat for hematologic (1)
A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia (1)
Calcium Mobilization and Enhanced Natural Killer Function in Large Granular Lymphocytes Result from Cross-Linking the CD2 E-Rosette and CD16 Fc-Receptor (1)
The role of CD4+CD25+ T regulatory (Treg) cells in allogeneic bone marrow transplantation (1)
Establishing Safety in the Clinic for the First Lentiviral Vector To Be Tested in Humans. (1)
Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells. (1)
Abstract PL03-01: CAR T cells for leukemia and more (1)
Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia (1)
Development of novel substrates for tumor immunotherapy. (1)
Rapid T Cell Recovery and Possible Auto-GVHD Following Adoptive Transfer of Ex-Vivo Costimulated Autologous T Cells at Day +2 Post-Transplant. (1)
CAR T Cell Cytotoxicity Is Dependent on Death Receptor-Driven Apoptosis (1)
Scholler Antigen Receptor T Cells Decade-Long Safety and Function of Retroviral-Modified Chimeric (1)
Abstract 4701: NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming (1)
Selective Reprogramming of Cd19-Specific T Cells With IL-21 and CD28 Signaling for Adoptive Immunotherapy of Acute Lymphoblastic Leukemia (1)
Chimeric Immunoreceptor (T-Body) Targeting of Acute B-Cell Lymphoblastic Leukemia (B-ALL) through Lentivirus Engineering of Primary Human T Cells. (1)
T-Rapa6 and T-Rapa12 Cells Differentially Mediate Acute Gvhd after Low-Intensity Allogeneic HCT (1)
Randomized phase II trial of combination idiotype vaccine and anti-CD3/anti-CD28 costimulated autologous T cells in patients with multiple myeloma post-autotransplantation (1)
Cytokine Release Syndrome in Severe COVID 19: Lessons From Arthritis and Cell Therapy in Cancer Patients Point to Therapy for Severe Disease (1)
In Vitro Induction of Human Regulatory T-Cells (iTregs) Using Conditions of Low Tryptophan Plus Kynurenines (1)
Abstract PR07: Human chimeric antigen receptor (CAR) macrophages for cancer immunotherapy (1)
Abstract 2900: IMCgp100: A novel bi-specific biologic for the treatment of malignant melanoma (1)
1075. Phase I Clinical Trial Demonstrates Safety and Feasibility of Autologous Cellular Therapy with Lentiviral Modified CD4 T Cells Expressing Anti-HIV Antisense in Patients with HAART Resistant HIV-1 Infection (1)
Anti-CD 3 / Anti-CD 28 Monoclonal Antibody – Coated Suture Enhances the Immune Response of Patients With Head and Neck Squamous Cell Carcinoma (1)
myeloablation using chimeric antigen receptor Preclinical targeting of human acute myeloid leukemia (1)
CAR T-Cells Depend on the Coupling of NADH Oxidation with ATP Production (1)
Chimeric antigen receptor modified T cells directed against CD19 (CTL019) induce clinical responses in patients with relapsed or refractory CD19+ lymphomas (1)
Adoptive Cellular Therapy With Synthetic T Cells as an “Instant Vaccine” for Cancer and Immunity (1)
Cytokine Storm. Reply. (1)
Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT (1)
Activation of human b lymphocytes by nanogram concentrations of anti igm coupled to dextran (1)
Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells (1)
Decade-long remissions of leukemia sustained by the persistence of activated CD4+ CAR T-cells (1)
Autologous aGVHD Associated with Infusion of T-Cells with Engineered Specificity for NY-ESO-1 and LAGE-1 Following High-Dose Melphalan and ASCT in Patients with Multiple Myeloma (1)
Phase 1 Trial of Cyclosporine for Hospitalized Patients with COVID-19 (1)
Abstract B139: Toxicity testing of EGFRvIII CAR-based immunotherapy of glioblastoma: From bench to bedside (1)
Abstract 3187: Depleting cells expressing fibroblast activation protein disrupts tumor-promoting desmoplasia (1)
Effective targeting of primary human acute myeloid leukemia using anti-CD123 chimeric antigen receptor engineered T cells (1)
Impact of CAR T-cell product viability on B-cell lymphoid malignancy outcomes (1)
Results of a Phase I/II Randomized Immunotherapy Trial Testing Adoptive Transfer of Co-Stimulated Autologous T Cells and Pneumococcal Conjugate Vaccine (PCV) Immunization after Autotransplantation for Myeloma (MM). (0)
Schedule Dependent Effects of Adoptively Transferred Autologous T Cells After AutoSCT for Myeloma: Accelerated Immune Recovery Is Associated with Improved Event-Free Survival. (0)
Stimulation of the antigen receptor complex leads to transcriptional activation of the c-myc gene in normal human T cells. (0)
CD 28 co-receptor signal transduction in T-cell activation (0)
Pre-clinical development of multiplex-CRISPR-edited cell and gene therapy products (0)
Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function (0)
Abstract PL07-04: Engineered T cell transfer for cancer immunotherapy in the era of synthetic biology: Challenges and opportunities. (0)
Abstract 4574: Use of CD19-targeted Chimeric Antigen Receptor-modified T (CART19) cells in ALL and CLL produce transient cytokine release syndrome (CRS), macrophage activation syndrome (MAS) and durable responses. (0)
B‐cell maturation antigen chimeric antigen receptor T‐cell re‐expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor‐based combination therapy (0)
Adoptive Immunotherapy with Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy in Patients with Chronic Lymphocytic Leukemia (0)
Meeting Report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010 (0)
A Phase II Randomized Study of HIV-Specific T-Cell GeneTherapy in Subjects with Undetectable Plasma Viremiaon Combination Antiretroviral Therapy (0)
Use of modified T lymphocytes with chimeric antigen receptors to treat cancer (0)
with umbilical cord blood: safety profile and detection kinetics Infusion of ex vivo expanded T regulatory cells in adults transplanted (0)
Cell therapy for cancer – our synthetic future (0)
Adoptive Transfer of Autologous CD25-Depleted, CD3/CD28-Costimulated T Cells After Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma: Long-Term Follow up (0)
Peripheral NK Cell Activation and Expansion by Artificial Antigen Presenting Cells, 2D11 (0)
79 – Tumor immunology and immunotherapy (0)
PS1134 CHRONIC LYMPHOCYTIC LEUKEMIA CELLS IMPAIR MITOCHONDRIAL FITNESS IN T CELLS AND IMPEDE CAR T CELL EFFICACY (0)
Cancer treatment using a chimeric receptor antigen anti-CD19 (0)
Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19 (0)
Single-Dose Intrapleural IFN-B GeneTransfer forMalignant PleuralMesotheliomaandMetastatic Pleural Effusions : HighRate ofAntitumor ImmuneResponses (0)
Splenic B-Cells From Maids Mice Show a Selective Defect in Tyrosine Phosphorylation in Response to Igm Cross-Linking (0)
Immunotherapy with inclusion of CD28 stimulation (0)
Abstract P6-10-08: Preliminary results of a first in human Phase 1 clinical trial to demonstrate safety and feasibility of chimeric antigen receptor T (CART) cells directed against c-Met in the treatment of breast cancer (0)
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma (0)
T Cells Demonstrate Enhanced Specificity for CD19 + Malignancies When Stimulated with IL-21. (0)
Abstract 2933: Pre-clinical model of eradication of B cell leukemia with lentiviral transduced anti-CD19 chimeric immunoreceptor-modified T cells (0)
Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells (0)
A Preclinical Model Tto Study Tumor-Infiltrating Lymphocyte (TIL) Anergy/Exhaustion In Adoptive T Cell Therapy (ACT) Of Thoracic Malignancies (0)
The NFAT-1 DNA binding complex in activated T cells contains Fra-1 and JunB (0)
Signaling Domain of Chimeric Antigen Receptors Can Reprogram T Cells (0)
Evaluation of the CD8+ Tumor Associated vs. Non-Tumor Associated Immune Repertoire in Cancer Patients Following Induction of Lymphopenia and Following CD3/4-1BB Based Expansion. (0)
Use of CD28 agonists to refill the T-cell tank? (0)
cis-acting sequences required for inducible interleukin-2 enhancer function bind a novel Ets-related protein, Elf-1 (0)
Glycopeptide-Specific Chimeric Antigen Receptor Targeting of T Cell Leukemia (0)
77 – Tumor immunotherapy (0)
Tar geting the Cancer-AssociatedTn-Glycoformof theMembraneMucinMUC 1 Control Adenocarcinoma Highlights (0)
Multi-Center Phase I Study of Th1/Tc1 Immunotherapy Following Autologous Hematopoietic Progenitor Cell Transplantation in Reccurrent or High Risk Plasma Cell Myeloma (0)
Characterization of autologous T cells engineered to express NY-ESO-1 TCR with multiplexed CRISPR/Cas9 editing (NYCE T Cells) (0)
Abstract 3139: CD33 directed chimeric antigen receptor T cell therapy as a novel regimen prior to allogeneic stem cell transplantation in acute myeloid leukemia (0)
T-Lymphocytes: Mature Polyclonal and Antigen-Specific Cell Culture (0)
Novel Redirected T Cell Immunotherapies for Advanced Prostate Cancer. (0)
COLIGATION OF CD40L (CD154) AND CD3 RESULTS IN CD4+ T CELL ACTIVATION AND THE INDUCTION OF APOPTOSIS. (0)
Rapamycin-Induced Autophagy Generates Anti-Apoptotic Th1/Tc1 Cells That Mediate Increased Xenogeneic Gvhd. (0)
RENAL COMPUTED TOMOGRAPHY IS ABNORMAL IN PYELONEPHRITIS (0)
CTLA 4 Require CD 28 Costimulation and Are Regulated Nucleic Acid Vaccine-Induced Immune Responses (0)
Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8+ T Cells and Impede CAR T Cell Efficacy (0)
Abstract 4575: Correlates of clinical response following autologous stem cell transplant and adoptive immunotherapy with engineered T cells expressing an affinity-enhanced T cell receptor in patients with mutliple myeloma. (0)
Regulation of 4F2 heavy-chain gene expression during normal human T-cell activation can be mediated by multiple distinct molecular mechanisms (0)
Abstract KN01: Updates on engineered T cells as cancer therapies (0)
Immunoregulation recourant a la voie d'acces du cd28 (0)
IMMUNOTHERAPY IN CANCER 1 (0)
Mesothelin expression as a predictive biomarker of breast cancer outcomes. (0)
Abstract 60: Induction of T cell dysfunction and NK-like T cell differentiation in vitro and in patients after CAR T cell treatment (0)
ression of Human Disseminated Tumor (0)
Primary Human CD 4 T Lymphocytes , and IL-2 Expression inL 3-Kinase , Bcl-x Distinct Regulation of Phosphatidylinositol Src Homology 2 Binding Domains Show CD 28 and Inducible Costimulatory Protein (0)
Durable Remissions with Control of Cytokine Release Syndrome (CRS) Using T Cells Expressing CD19 Targeted Chimeric Antigen Receptor (CAR) CTL019 to Treat Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) (0)
Continued observation and the collection of more data will be required to better define the relationship between skin lesions and CAR T-cell therapies (0)
Human T Cell Rapamycin Resistance And Th1/Tc1 Polarization Augment Xenogeneic Graft-Versus-Host Disease (0)
Model Cell Differentiation from a Human Cell Line Progenitor to Dendritic + Pathways in CD 34 Evidence for Distinct Intracellular Signaling (0)
990. Unexpected Immune Enhancement by Autologous Lentiviral Modified CD4 T Cells: Results from a Phase I Gene Transfer Trial of Lentiviral Vector-Modified T Cells Expressing Antisense Envelope (0)
719. Combination of ICOS and 4-1BB in a Third Generation CAR Exhibits Enhanced T Cell Persistence and Increased Antitumor Effect (0)
4-1BB is Superior to CD28 Costimulation for Generating Effector CD8+ T Cells for Adoptive Immunotherapy (0)
SP-024 CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS FOR RELAPSED,REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (0)
Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (0)
Antibody and B 7 / BBl-mediated Ligation of the CD 28 Receptor Induces Tyrosine Phosphorylation in Human T Cells (0)
Immunotherapy Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma (0)
Abstract 3505: Preclinical testing of mRNA engineered chimeric antigen receptor T cells: Comparison of a multi-infusion protocol to a single injection of stably expressed CARs in ALL xenograft models (0)
Oral presentations (0)
1108. High Rate of Anti-Tumor Immune Responses in a Phase 1 Clinical Trial of Adenoviral-Interferon-Beta Gene Transfer for Malignant Mesothelioma (MM) and Malignant Pleural Effusions (MPE) (0)
Management of the Critically Ill Marrow Transplant Patient (0)
Abstract 1787: ImmTACs: Bi-functional reagents for redirected tumour cell killing (0)
Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT (0)
Genetically Modified T Cells for Human Gene Therapy (0)
Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy. (0)
Abstract 4706: TCR engineered adoptive T-cell therapy for lung cancer is augmented by combined PD1 and TIM3 antibody blockade (0)
A Randomized Phase II Trial of Idiotype Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients. (0)
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor (0)
Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. (0)
An inducible cytoplasmic factor (AU-B) binds selectively to AUUUA multimers in the 3' untranslated region of lymphokine mRNA (0)
Innovative artificial antigen presenting cells and uses thereof (0)
Abstract 5616: Soluble, high affinity TCRs fused to anti-CD3 redirect T cells to kill cancer cells presenting MAGE-A3 and NY-ESO antigens (0)
Can't get any help? New approaches for adoptive immunotherapy of cancer. (0)
CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL (0)
Artificial Antigen Presenting Cells (aAPC) Expanded NK-Mediated Enhanced Lysis of Allogeneic Tumor Cells Regardless of HLA Class I/KIR Mismatch and Its Implication of Use in Eradicating Acute Lymphoblastic Leukemia (ALL). (0)
Procedes de stimulation selective de la proliferation des lymphocytes t (0)
Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells (0)
Vision: Cancer gene therapy at the crossroads (0)
Abstract 4744: Soluble, high affinity TCRs fused to anti-CD3 redirect T cells to kill cancer cells presenting MAGE-A3 and NY-ESO antigens (0)
Abstract IA20: Updates on CAR T Cells (0)
Abstract 4961: Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12 (0)
555. Large-Scale, Flow-Based Electroporation To Deliver Engineered Zinc Finger Protein Nucleases That Mediate High-Efficiency Disruption of the Human CCR5 Gene (0)
176 Exploring the Potential of CCR5 and CXCR4 Modified CD4 T Cells to Target the HIV-1 Reservoir (0)
Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects (0)
Keli L . Hippen with Minimal Loss of in Vivo Functional Activity ) regsMassive ex Vivo Expansion of Human Natural Regulatory T Cells ( T (0)
Sleeping Beauty (SB) Transposon Mediated Umbilical Cord Blood (UCB) T Cell Therapy for Refractory Acute Lymphoblastic Leukemia (ALL). (0)
Allogeneic Antitumor Vaccine Strategies (0)
A novel switchable car-T cell therapy for tumor retargeting and improved safety (0)
modified T cells - myeloablation using chimeric antigen receptor Preclinical targeting of human acute myeloid leukemia and (0)
Optimizing Adoptive T Cell Transfer (ACT) Immunotherapy For Malignant Pleural Mesothelioma (MPM) (0)
B107 Results of a phase 1 using CCR5 Deficiency with Zinc Finger Nuclease-modified Autologous CD4 T Cells (SB-728-T) in HIV-infected Subjects (0)
Abstract 3798: Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells (0)
Role of the CD4 Receptor in Human T Lymphocyte Signalling: Effects of HIV-1 Infection on Human T Cell Activation (0)
Physicians Abstracts (0)
PD-L1 Immuno-Gene Therapy Under Cell Fate Control: Persistence of Cellular Delivery Vehicle and Transgene Expression. (0)
Cells: Evidence for Protein Kinase C-Mediated Hemopoietic Progenitors to Dendritic + CD34Esters Induce Differentiation of Human (0)
Cell Differentiation from a Human Cell Line Pathways in CD34+ Progenitor to Dendritic Evidence for Distinct Intracellular Signaling (0)
A Novel Small Animal Model to Test on-Target Off-Tumor Cytoxicity of Adoptive Immune Therapies (0)
Precision Immunotherapy of Cancer (0)
Adoptive Immune Responses to Sars-Cov2 Vaccination in CART19 Treated Patients (0)
Treatment of cancer using humanized chimeric anti-CD19 antigen receptor (0)
A phase I/II trial of IDD-6, an autologous dendritic cell vaccine for women with advanced ovarian cancer in remission (0)
Vector Integration and Efficacy of CD19-Directed CAR T Cell Therapy in Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL) (0)
Abstract 3528: IMCmage1: A novel bi-specific biologic re-directing T cells to kill MAGE-A3/A6 presenting cancers (0)
PRIMARY HIV ISOLATES THAT ARE DUAL-TROPIC FOR THE CHEMOKINE RECEPTORS ccR5 AND cxcR4 (FUSIN, LESTR): 53 (0)
Adoptive immunotherapy with tumor-derived donor lymphocytes after allogeneic hematopoietic stem cell transplantation (0)
Abstract 3972: Carpet bombing with CARs: Influence of dose, timing, lymphodepletion and costimulatory domain on efficacy of mRNA engineered anti-CD19 Chimeric Antigen Receptor T cells in preclinical xenograft models. (0)
516. Chimeric Antigen Receptors With Distinct Signaling Domains Can Reprogram T Cells (0)
Pilot Clinical Trial of Adoptive Immunotherapy with Chimeric, Co-Stimulated Tumor-Infiltrating Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation. (0)
Abstract IA10: CARs for leukemia and beyond? (0)
510. Treating Epithelial and Metastatic Malignancies with Glycoform-Specific Chimeric Antigen Receptors (0)
Abstract LB-053: Next-generation sequencing of T-cell receptor-beta gene rearrangements reveals dramatic expansion of T-cell clonotypes after CART-EGFRvIII therapy for glioblastoma (0)
Flow cytometry in the evaluation of immune status in cancer and HIV infection. (0)
NEXT GENERATION CAR T CELLS FOR LYMPHOMA AND BEYOND (0)
Procedes ameliores de transfection des lymphocytes t (0)
A Phase 1 Dose Escalation Study of Infusion of Ex Vivo CD3/CD28 Costimulated Umbilical Cord Blood-Derived T Cells in Adults Undergoing Transplantation for Advanced Hematologic Malignancies (0)
131 Genetic disruption of negative immune regulators to enhance CAR-T efficacy against solid tumors (0)
Costimulated, Tumor-Derived Donor Lymphocyte (TDL) Infusion for B-Cell Tumor Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (0)
Cell Proliferation T Cancer Patients Directly Inhibit Autologous Cutting Edge: Regulatory T Cells from Lung (0)
1106. Results of a Phase I Clinical Trial of Adenoviral-Interferon-Beta Gene Therapy for Malignant Mesothelioma and Malignant Pleural Effusions (0)
Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy (0)
Abstract IA16: Engineered T cell therapies for cancer. (0)
CellsHHuman T The Inducible Costimulator ( ICOS ) Is Critical for the Development of (0)
Selective killing of malignant B cells using T cells redirected against malignancy variant receptor (0)
Combinatorial IL13Rα2 chimeric antigen receptor-T cells plus checkpoint blockade to treat solid tumors in murine and canine models. (0)
The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. (0)
The CD 45 Tyrosine Phosphamse Regulates Phosphotyrosine Homeostasis and Its Loss ReveMs a Novel Pattern of Late T Cell Receptor-induced Ca 2 + Oscillations (0)
Abstract 3968: Ovarian cancer chemokine microenvironment is conducive to homing of CD3/CD28 co-stimulated T cells prepared for adoptive transfer therapy. (0)
expressed on artificial antigen-presenting cells of tumor necrosis factor receptor family members OX40 and 4-1BB Umbilical cord blood regulatory T-cell expansion and functional effects (0)
HIV conditionally replicating lentiviral vector expressing long antisense to Antiviral effects of autologous CD 4 T cells genetically modified with a (0)
Anti-CD123 chimeric antigen receptor redirected T cells for relapsed B-cell acute lymphoblastic leukemia (0)
Abstract IA01: Single cell analysis of CRISPR T cells (0)
Prevention of Acute GVHD by Ex Vivo Expanded Umbilical Cord Blood Derived Regulatory T Cells (Treg) (0)
Cancer esearch oenvironment and Immunology tiple Injections of Electroporated Autologous T Cells ressing a Chimeric Antigen Receptor Mediate R ression of Human Disseminated Tumor (0)
Abstract B05: A biologic screen to evaluate potential toxicity of chimeric antigen receptor modified T cells against primary normal human tissues (0)
Intact function of TIL and PBL T cells from early stage NSCLC (0)
A phase 0 exploratory study to assess the pharmacodynamic effects of single intratumoral dose of a novel bispecific targeting/immune-activating agent on the melanoma tumor microenvironment. (0)
CART-Cell Therapies inGlioblastoma:AFirst Look (0)
Costimulatory Requirements for the Expansion of Human T Regulatory Cells (0)
Expansion of Functional Polyclonal Human T-regulatory Cell Lines Using Artificial Antigen Presenting Cells and Rapamycin. (0)
Immune regulation on the CD28-route (0)
Abstract PR14: Fibroblast activation protein as a universal target for chimeric antigen receptor T cell therapy in solid tumors. (0)
acute graft-versus-host disease but retain graft-versus-leukemia activity activated CD44hiCD8+ T cells are defective in mediating - Dendritic cell (0)
Abstract IA13: Engineered T cells for cancer therapy (0)
That Inhibits Interleukin-2 Secretion but Allows Unique Signal to Resting Human CD4 T Cells Cutting Edge: CTLA-4 Ligation Delivers a (0)
Mitogen-induced genes are subject to multiple pathways of regulation in the initial stages of T-cell activation (0)
Preemptive T-Rapa Cell DLI after Low Intensity Allogeneic HCT May Allow for Improved Overall Survival in High Risk Lymphoid Malignancies (0)
Ex Vivo Manufacture of Rapamycin-Resistant Human Th1/Tc1 Cells. (0)
The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies (0)

This paper list is powered by the following services:

Other Resources About Carl H. June

en.wikipedia.org

What Schools Are Affiliated With Carl H. June?

Carl H. June is affiliated with the following schools:

Carl H. June's AcademicInfluence.com Rankings